Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma is a primary bone malignancy with significant mortality.
• Long noncoding RNAs (lncRNAs) are emerging as critical regulators in cancer development.
• HAGLROS (HOTAIR/HAGLROS) is a lncRNA whose role in osteosarcoma remains largely unexplored.

Purpose of the Study:

• To investigate the expression pattern of HAGLROS in osteosarcoma.
• To evaluate the prognostic significance of HAGLROS in osteosarcoma patients.
• To determine if HAGLROS can serve as a potential therapeutic target.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure HAGLROS expression in tumor and normal tissues.
• Chi-square tests analyzed the association between HAGLROS expression and clinicopathological features.
• Kaplan-Meier and Cox proportional hazards models assessed survival outcomes.

Main Results:

• HAGLROS was significantly upregulated in osteosarcoma tissues and cell lines compared to normal bone (p < 0.01).
• Upregulated HAGLROS correlated with advanced TNM stage (p=0.023), distant metastasis (p=0.002), and poor differentiation (p=0.021).
• Higher HAGLROS expression was linked to poorer overall survival (p=0.012) and disease-free survival (p=0.003), confirmed as an independent prognostic factor (p=0.002 for OS, p=0.001 for DFS).

Conclusions:

• HAGLROS is frequently overexpressed in osteosarcoma.
• HAGLROS expression is associated with aggressive clinicopathological features and poor patient outcomes.
• HAGLROS serves as an independent predictor of unfavorable prognosis and a potential therapeutic target in osteosarcoma.